Preclinical stage pharmaceutical company N8 Medical has just announced that its proprietary Ceragenin Technology was the subject of two recent reviews published in peer-reviewed journals that showcased the platform’s breakthrough ability to act as a broad-spectrum solution to bacterial infections, including those acquired from hospitalization, contaminated medical devices, and respiratory infections linked to cystic fibrosis. Ceragenins are cationic steroidal antimicrobials or CSAs, which are synthetic, non-peptide small molecule mimetics of endogenous host defense or antimicrobial peptides.
To date, more than 100 CSAs have been successfully synthesized, equipped with antimicrobial, anti-inflammatory, immunomodulatory, and anti-cancer properties. Of particular focus is N8 Medical’s CSA-13, which offers potent, rapid-acting antimicrobial properties, capable of addressing even multidrug resistant strains of Methicillin-resistant Staphylococcus aureus (“MRSA”) and Pseudomonas aeruginosa.
“Review articles such as these continue to validate our clinical hypotheses, encouraging our march to the clinic,” said Dr. Michael Triplett, CEO of N8 Medical. “Further, they demonstrate the multiple applications for ceragenins, which may ultimately provide N8 Medical with multiple opportunities for fighting bacterial infections, both in the near term as coatings for medical devices and in the longer term as potential therapeutics.”
[adrotate group=”3″]
The first platform review was published in MedChemComm, and written by Dr. Ido Herzog and Dr. Micha Fridman of the Royal Society of Medicine. They highlighted CSA-13’s great potential to be developed into antibiotic agents that can safely and effectively prevent formation of biofilm on medical devices and equipment. The second review is published in Studia Medyczne, which outlined a number of bacterial strains CSAs can effectively target and eradicate, particularly in infections precipitated by cystic fibrosis. CSA-13’s bactericidal, antiparasitic, antiviral, and anticancer activity was also reviewed as a promising component in future controlled release mechanisms and gene delivery.
N8 Medical, Inc., based in Columbus, Ohio, is a preclinical biotechnology company that specializes in researching and developing anti-infective solutions indicated for the treatment of chronic infections associated with cystic fibrosis, and antimicrobial agents for the prevention of biofilm formation known to cause medical device-related hospital acquired infections. N8 Medical is developing first-in-class, groundbreaking anti-infective agents that may mimic immune system function.